AMGN Amgen Inc.

Healthcare · Drug Manufacturers - General

4 · Weak Momentum 9.0 · Strong Watch 14y streak

414.30

-0.70%

About the company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Website Annual reports (10-K)

2.43%

62.61%

10.08

223.6B

25.73

16.10

347.52

52-week range

414

low 270 high 422

Dividend deep dive

Amgen Inc., a healthcare company in the Drug Manufacturers - General sector, currently offers a dividend yield of 2.76%. This yield is below its 5-year average of 3.16% and also below its 5-year historical low of 2.99%. According to its data, the company's dividend safety status is currently designated as 'watch'.

Dividend history

Amgen has an active dividend increase streak of 14 consecutive years, earning it the CCC 'contender' tier status. The 3-year dividend growth rate (CAGR) stands at 7.05%, while the 5-year CAGR is 8.27%. The company pays a quarterly dividend, typically in February, May, August, and November. Annual dividends have steadily increased from $2.44 in 2014 to $8.52 in 2023, with projected dividends of $9.00 for 2024 and $9.52 for 2025.

Dividend safety

Amgen's dividend safety is rated as 'watch'. The payout ratio is 70.1% of earnings per share. Leverage appears elevated, with a debt-to-equity ratio of 623.754.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.